ClinicalTrials.gg
CompletedNCT02876510ACTologUpdated Feb 4, 2025

ACTolog in Patients With Solid Cancers

A Phase 1 interventional study of Fludarabine and Cyclophosphamide in Cancer and Solid Tumor, sponsored by Immatics US, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Immatics US, Inc. · Phase 1, Interventional, and Treatment

How we know · 19 judgments

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.

Read the detailed description

SCREENING: Patient eligibility will be determined by HLA (human leukocyte antigen) and the main biomarkers screening. If the patient is eligible, white blood cells will be collected with a leukapheresis for the manufacture of the IMA101 product.

MANUFACTURE: IMA101 product will be made from the patient's white blood cells.

TREATMENT: IMA101 product will be administered to the patient intravenously after lymphodepleting pre-conditioning with chemotherapy (fludarabine and cyclophosphamide).

Low-dose IL-2 will be self-administered twice daily for a total of 28 doses after infusion of IMA101 product. In Cohort 2, atezolizumab will be administered every 3 weeks, starting no earlier than 3 weeks after the IMA101 product infusion and after hematologic recovery.

Patients will be monitored closely throughout the study.

02

Conditions studied

  • Cancer
  • Solid Tumor

Keywords

  • Ovarian Cancer
  • Esophageal Cancer
  • Head and neck squamous cell carcinoma
  • non-small cell lung cancer
  • Gastric Cancer
  • T-cell Therapy
  • immunotherapy
  • adoptive cellular therapy
  • T-cell receptor
  • cell therapy
  • cytotherapy
  • IMA101
  • atezolizumab
  • Tecentriq
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 38 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Immatics US, Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have confirmed advanced/ cancer prior to enrollment.
  2. HLA phenotype positive.
  3. (ECOG) performance status 0-1.
  4. > 6 months prior to enrollment.
  5. Patient is a candidate for a maximum of one further line of established therapy (prior to treatment with ACTolog).
  6. The patient has adequate organ and marrow function per protocol
  7. At least one lesion (metastasis or primary tumor) being considered accessible by non-high-risk collection procedures for .
  8. The patient has adequate hepatic function per protocol
  9. The patient has serum ≥50 mL/min by the Cockcroft-Gault formula.
  10. The patient has adequate pulmonary function per protocol
  11. Acceptable coagulation status
  12. Women of must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  13. Male subjects must agree to use effective contraception or abstinence while on study and for 90 days after infusion of the ACTolog T-cell product.
  14. Ability of subject to understand and the willingness to sign written for study participation.
  15. Confirmed availability of production capacities for the patient's ACTolog products.
  16. ACTolog target expression as evaluated by the in vitro diagnostic device IMA_Detect: Patient's tumor must express at least one ACTolog target as assessed by quantitative PCR (qPCR) (to be assessed from a tumor biopsy to be performed if all other eligibility criteria are met).

Exclusion criteria

Exclusion Criteria

  1. Any condition contraindicating leukapheresis.
  2. Patients with . Patients with a history of brain metastases may be eligible, if an imaging scan with contrast enhancement not older than 4 weeks is able to exclude the existence of currently active brain metastasis.
  3. infection, active or C infection, or active infections requiring oral or intravenous antibiotics or that can cause a severe disease and pose a severe danger to lab personnel working on patients' blood or tissue. If positive test results are not indicative of an active infection, patients can be included.
  4. Treatment with excluded therapy per protocol
  5. Previous extensive radiotherapy to the lung or liver during the last 4 months prior to lymphodepletion regimen.
  6. The patient has cardiac conditions defined per protocol
  7. Patients with prior stem cell transplantation or solid organ transplantation.
  8. The patient has concurrent severe and/or uncontrolled medical disease that could compromise participation in the study
  9. Active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, abdominal carcinomatosis or other known risk factors for bowel perforation.
  10. History of other (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years.
  11. The patient is pregnant or is breastfeeding.
  12. Serious disease per protocol
  13. History of to cyclophosphamide, fludarabine or IL-2.
  14. , not related to prior treatment for malignancy.
  15. History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician.
  16. Patients with Grade 3 or higher immune-related toxicities related to prior
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    IMA101 product only (Cohort 1)

    * Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide * Infusion of the IMA101 T-cell product(s) * Post-infusion administration of low-dose recombinant human interleukin-2

    Drug: Fludarabine · Drug: Cyclophosphamide · Biological: IMA101 product · Biological: Recombinant human interleukin-2 · Diagnostic Test: IMADetect

  • Experimental
    IMA101 product + atezolizumab (Cohort 2)

    * Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide * Infusion of the IMA101 T-cell product(s) * Post-infusion administration of low-dose recombinant human interleukin-2 * Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year

    Drug: Fludarabine · Drug: Cyclophosphamide · Biological: IMA101 product · Biological: Recombinant human interleukin-2 · Diagnostic Test: IMADetect · Drug: Atezolizumab

Interventions

  • Fludarabine infusion

    Also known as: Fludarabine monophosphate

  • Cyclophosphamide infusion

    Also known as: Cytoxan

  • BiologicalIMA101 product

    i.v. infusion of IMA101 product(s).

  • BiologicalRecombinant human interleukin-2

    Drug pages: AldesleukinStudies of AldesleukinAldesleukin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Interleukin-2Studies of Interleukin-2Interleukin-2 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Low dose IL-2 Infusion for two weeks

    Also known as: Aldesleukin, Proleukin

  • Diagnostic testIMADetect

    IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.

  • Atezolizumab infusion will be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 1 year after IMA101 infusion.

    Also known as: Tecentriq

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (Safety and tolerability) of IMA101 alone or in combination with atezolizumab

    Time frame: up to 18 months

Secondary outcomes

  1. Peripheral T-cell persistence (assessment of frequency of T-cells over time)

    Time frame: up to 18 months

  2. Tumor response per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and immune-related RECIST (irRECIST)

    Time frame: up to 18 months

07

Study locations

1 site
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Publications

  • Fritsche J, Rakitsch B, Hoffgaard F, Romer M, Schuster H, Kowalewski DJ, Priemer M, Stos-Zweifel V, Horzer H, Satelli A, Sonntag A, Goldfinger V, Song C, Mahr A, Ott M, Schoor O, Weinschenk T. Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection. Proteomics. 2018 Jun;18(12):e1700284. doi: 10.1002/pmic.201700284. Epub 2018 Apr 10. PubMed 29505699 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Sep 2021, 50 months.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 50 months is above that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2016
First posted
Aug 23, 2016
StartActual
Jun 30, 2017
Primary completionActual
Sep 22, 2021
CompletionActual
Sep 22, 2021
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02876510
Lead sponsor
Immatics US, Inc.
Responsible party
Sponsor
First posted
Aug 23, 2016
Start date
Jun 30, 2017
Primary completion
Sep 22, 2021
Completion
Sep 22, 2021
Last update
Feb 4, 2025

Study contacts

Cedrik Britten, M.D.
study director · Immatics US, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion